Literature DB >> 7312007

Effects of estrogens and progestins on the biochemistry and morphology of the postmenopausal endometrium.

M I Whitehead, P T Townsend, J Pryse-Davies, T A Ryder, R J King.   

Abstract

To study the effects of exogenous estrogens on the postmenopausal endometrium, and to determine the time course and minimum dosage of added progestins necessary to oppose estrogen stimulation, we obtained endometrial specimens from symptomatic postmenopausal women being treated with various preparations of estrogens and progestins. Morphologic changes were assessed with light and electron microscopy, and biochemical effects through measurement of DNA synthesis, estradiol and progesterone receptors, and isocitric and estradiol dehydrogenase activity. For comparison, identical studies were carried out on specimens from premenopausal women in the proliferative and secretory phases of their cycle. All the estrogens exerted stimulatory effects in the postmenopausal specimens that were comparable to those observed in the premenopausal proliferative-phase specimens. Estropipate, subcutaneous estradiol, and conjugated estrogens had some hyperphysiologic effects. Maximal progestational effects occurred in the postmenopausal specimens only after norethindrone was administered for six days, and a constant level of activity equal to that in premenopausal secretory-phase specimens was then observed until the 10th day of exposure. Similar maximal effects occurred after six days of treatment with D/L-norgestrel (150 and 5 mg daily [10 mg daily produced less complete changes]). We conclude that many estrogen preparations subject the endometrium to a potent stimulus. Norethindrone and norgestrel are protective because they counteract the proliferative effects of estrogens, but the currently recommended daily dosages of these progestins can be greatly reduced without loss of response.

Entities:  

Mesh:

Substances:

Year:  1981        PMID: 7312007     DOI: 10.1056/NEJM198112313052701

Source DB:  PubMed          Journal:  N Engl J Med        ISSN: 0028-4793            Impact factor:   91.245


  41 in total

Review 1.  Pharmacokinetics and potency of progestins used for hormone replacement therapy and contraception.

Authors:  Frank Z Stanczyk
Journal:  Rev Endocr Metab Disord       Date:  2002-09       Impact factor: 6.514

2.  Continuous combined hormone replacement therapy and endometrial hyperplasia.

Authors:  David F Archer
Journal:  BMJ       Date:  2002-08-03

Review 3.  The menopause and hormone replacement therapy.

Authors:  K T Khaw
Journal:  Postgrad Med J       Date:  1992-08       Impact factor: 2.401

Review 4.  A risk-benefit assessment of estrogen therapy in postmenopausal women.

Authors:  M P Cust; K F Gangar; T C Hillard; M I Whitehead
Journal:  Drug Saf       Date:  1990 Sep-Oct       Impact factor: 5.606

Review 5.  [The role of progestins].

Authors:  H I Wyss
Journal:  Arch Gynecol Obstet       Date:  1989       Impact factor: 2.344

Review 6.  Hormonal replacement therapy for postmenopausal women: a review of sexual outcomes and related gynecologic effects.

Authors:  M Walling; B L Andersen; S R Johnson
Journal:  Arch Sex Behav       Date:  1990-04

7.  Prevention of early postmenopausal bone loss using low doses of conjugated estrogens and the non-hormonal, bone-active drug ipriflavone.

Authors:  D Agnusdei; C Gennari; L Bufalino
Journal:  Osteoporos Int       Date:  1995       Impact factor: 4.507

Review 8.  Transdermal estradiol/norethisterone. A review of its pharmacological properties and clinical use in postmenopausal women.

Authors:  L R Wiseman; D McTavish
Journal:  Drugs Aging       Date:  1994-03       Impact factor: 3.923

9.  Biological behavior of preneoplastic conditions of the endometrium: A retrospective 16-year study in south India.

Authors:  Shalinee Rao; Sandhya Sundaram; Raghavan Narasimhan
Journal:  Indian J Med Paediatr Oncol       Date:  2009-10

Review 10.  Drugs used in the treatment of metabolic bone disease. Clinical pharmacology and therapeutic use.

Authors:  S Patel; A R Lyons; D J Hosking
Journal:  Drugs       Date:  1993-10       Impact factor: 9.546

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.